Editorial RO Escárcega et al.
Autoimmune diseases are associated with higher rates of cardiovascular morbidity and mortality, primarily secondary to accelerated atherosclerosis. This phenomenon can be attributed to traditional risk factors for atherosclerosis and the use of specific drugs, such as corticosteroids, but also might be the result of other inflammatory mechanisms that are aggravated in autoimmune diseases. 1 Mounting evidence from a growing body of epidemiological studies demonstrate that patients with systemic lupus erythematosus (SLE) are at increased risk for the development of premature cardiovascular disease (CVD). Atherosclerosis is the most common cardiac abnormality. Although lesions of the valves, myocardium and pericarditis may all occur, cardiac manifestations are often mild and asymptomatic, and they can frequently be recognized by echocardiography and other noninvasive tests. 2 Coronary artery disease (CAD) is described in SLE patients with a prevalence ranging from 6 to 10%, and the risk of developing this manifestation is four to eight times higher than normal. 3 Moreover, acute myocardial infarction is the cause of death in 3-25% of SLE patients in different reports. 4 Managing conventional cardiovascular risk factors such as diabetes mellitus, smoking, hyperlipidemia and hypertension is reasonable, but over the years we have found that these traditional risk factors do not explain this increased risk for accelerated CAD. Esdaile, et al. 5 reported that cardiovascular events in patients with SLE had one or fewer conventional risk factors and that adjusting results to exclude the effect of the Framingham risk factors showed that patients with SLE still had higher risk of CAD (relative risk [RR] 7.5) and stroke (RR 7.9), which indicates that SLE itself constitutes an independent risk factor for the development of CAD. We have previously reported 6 that patients with SLE without traditional factors for coronary disease and low activity of the disease were not shown to have positive stress test in the first 10 years of the disease regardless of the corticosteroid dose, therefore managing the traditional risk factors for coronary disease along with strict disease control is mandatory for all the patients to decrease early cardiovascular morbidity.
Statins are now one of the cornerstone drugs in the management of CAD as they have been used for primary and secondary prevention of acute coronary syndromes. Recent evidence has shown that statin drugs mediate a number of biological actions, called pleiotropic actions, that go beyond the lowering of LDL cholesterol. 7 Recently, a trial named The Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) 8 trial showed that size of reduction in low density lipoprotein cholesterol (LDL-c) levels was not necessarily associated with the rate of progression in vascular disease, 8 thus the benefit of statins may not be restricted to lowering LDL alone, but mediating inflammation and stabilization of atherosclerotic plaque. The trial brought a paradox in which the relationship between LDL cholesterol reduction and atherosclerosis was questioned. Many investigators raised concerns on this particular trial including the rationale for the use of carotid intima-media thickness as a surrogate end point. In fact there has been several studies assessing the correlation between intima-media thickness and angiographic evidence of coronary atherosclerosis, most of them have shown a modest positive relationship, similar to that found in autopsy studies, 9 however, there is overwhelming evidence on the positive effect of statins and coronary events prevention. Thus, does ezetimibe when added to a statin provides no benefit? That question should be clarified in the up coming years with on going trials. Is this relevant to SLE patients? There is no data on how many patients with lupus are being treated with statins and/or ezetimibe, although we know that ezetimibe use in the United States was around 34 million prescriptions in 2006, as described by Jackevicious, et al. 10 It should be investigated whether ezetimibe when added to a statin has the same or enhanced pleiotropic effects on patients with underlying chronic inflammatory states such as autoimmune diseases. Ezetimibe blocks the absorption of cholesterol by blocking the Niemann-Pick C1-like 1 protein and thus lowers the LDL cholesterol, which in theory should reduce the risk for coronary events. In the ENHANCE trial C-reactive protein was lower in the ezetimibe group (6.6 vs 25.7%; P < 0.01), thus one can argue that even the intima-media thickness did not result in a significant difference when compared to a statin alone, the rate of 'inflammatory markers' reduction can make us think that overall in a longer follow-up the outcomes on coronary events might be lower if the missing piece of the puzzle in atherosclerosis is in fact chronic inflammation. The overall effect of statins of decreasing inflammatory markers, stabilization of the atherosclerotic plaque and a significant decrease in cardiovascular mortality is desirable for all patients with CAD. The idea of giving statins to all patients with SLE regardless of the LDL level is quite interesting. In fact, the pleiotropic actions of statins will be beneficial in patients with SLE such as decreasing the systemic inflammation represented by decreasing levels of C-reactive protein. Nevertheless, the widespread use of statins has been looked at by the Food and drug administration (FDA) 11 and they have recommended against it due to recent data that suggests that statins may not be as safe as we believe in patients that do not have hypercholesterolemia in which the risk of hemorrhagic stroke may be increased. Petri and colleagues 12 conducted a randomized controlled trial of Atorvastatin vs placebo. They concluded that Atorvastatin slowed the progression of intimal-medial thickness but at expense of increasing side effects, mainly muscle and liver toxicity. Statins, therefore, should be used with caution in patients without a high LDL levels. Lawman, et al., 13 showed that administration of Atorvastatin to lupus-prone New Zealand Black/White F1 mice resulted in a significant reduction in serum IgG anti-dsDNA antibodies and decreased proteinuria, thus demonstrating that Atorvastatin can delay the progression of a spontaneous autoimmune disease and may specifically benefit patients with SLE. In the future years, powered randomized control trials must be conducted to determine the long-term effect on CVD in patients with SLE.
Hypertension and diabetes are common in patients with SLE, 14 both induced by disease activity, systemic inflammatory state, obesity and corticosteroid use. 1 There is strong evidence base for the use of interventions affecting smoking, hypertension and diabetes to reduce cardiovascular risk in the general population. SLE patients are indeed different from the subjects included in most of the studies concerning cardiovascular risk reduction. Regardless of this difference, aggressive management of cardiovascular risk factors will decrease cardiovascular morbidity and mortality in SLE patients, which may not be enough to completely abate mortality due to premature CVD. Calculation of Framingham risk score is not enough to predict the 10-year risk of death in these patients. Therefore, SLE patients should be managed very early in the disease with life style modification and smoking cessation programs. The role of statins still needs to be clarified in longitudinal long-term follow-up studies. The optimal target of LDL-c, HbA1C and blood pressure still needs to be elucidated in SLE patients.
There are, however, additional nontraditional risk factors for coronary disease present in patients with SLE. Bruce, et al. 15 studied 250 women with SLE and 250 controls. They found that SLE patients had a higher level of very low density lipoprotein (VLDL), total triglycerides and higher levels of homocysteine. The homocysteine levels were found in 11% of SLE patients compared to only 0.8% of controls. This occurred despite higher overall red blood cell folate level. Homocysteine has been found to be an important risk factor for thrombosis in SLE, 16 although in the general population, the primary role of homocysteine as an independent risk factor for CAD remains controversial. 17 The management of these nontraditional risk factors is still controversial, although current recommendations encourage targeting non-LDL and non-high density lipoprotein (non-HDL) cholesterol once LDL-c target has been met.
Most of the autoimmune diseases have been associated with accelerated atherosclerosis. Antiphospholipid syndrome (APS) deserves especial attention as this disease does not follow the prototype of overwhelming systemic inflammation. This disease is characterized by recurrent thrombosis and anticardiolipin antibodies (aCL). Sherer, et al. 18 reported a prospective analysis where they found that the presence of aCL was associated with Myocardial infarction and death, and that those who had significant coronary-artery stenosis had elevated levels of aCL compared to those without significant coronary-artery stenosis. Thus, the role of inflammation alone might not explain the accelerated atherosclerosis seen in autoimmune diseases. In contrast to APS, rheumatoid arthritis (RA) is highly associated with systemic inflammation. Functional abnormalities of the endothelium have been found in distinct cohorts of patients with RA 19 which has been associated with higher rates of atherosclerosis. Recently, the role of endothelial dysfunction, especially the role of vascular endothelial growth factor (VEGF), was investigated in SLE patients. Colombo, et al. 20 published the traditional and nontraditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS) study. They found that SLE patients have increased mean intima-media thickness and VEGF values as compared with healthy age-matched controls, and that intima-media thickness and VEGF values are independently and directly associated with SLE disease, and thus they proposed that VEGF is a potential new marker of accelerated atherosclerosis in SLE.
The role of aspirin in primary and secondary prevention in the general population is well known 21 . When compared with placebo, aspirin therapy has been associated with a significant, 32% reduction in the risk of myocardial infarction, but the data on the risk of stroke and death from CVD remain inconclusive, 21 of note, most of the trials have included mostly men. SLE patients are in the vast majority women. Ridker, et al., 22 randomly assigned 39,876 initially healthy women 45 years of age or older to receive 100 mg of aspirin on alternate days or placebo and then monitored them for 10 years for a first major cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes). As compared with placebo, aspirin had no significant effect on the risk of fatal or nonfatal myocardial infarction (relative risk [RR], 1.02; 95% confidence interval [CI], 0.84-1.25; P = 0.83) or death from cardiovascular causes (RR, 0.95; 95% CI, 0.74-1.22; P = 0.68). The conclusion of this large, primary-prevention trial among women was that aspirin lowered the risk of stroke without affecting the risk of myocardial infarction or death from cardiovascular causes. Of note, subgroup analyses showed that aspirin significantly reduced the risk of major cardiovascular events, ischemic stroke and myocardial infarction among women 65 years of age or older.
After this landmark paper in the history of primary prevention, the role of aspirin for women remains controversial. Again the group studied differed substantially from most SLE patients. We cannot say that for aspirin, the older the better, but this drug appears to be more beneficial in older patients. Even there was a nonsignificant increase in the risk of hemorrhagic stroke and a significant increase in gastrointestinal bleeding. Aspirin should be added to SLE therapy as standard for primary prevention of stroke expecting the same effect in younger women. Whether it reduces the risk of myocardial infarction is still unknown and under investigation.
In conclusion, patients with SLE should be managed aggressively early in the disease by modifying traditional risk factors for coronary disease. Framingham risk should not be used to estimate cardiovascular risk as the disease itself and the use of corticosteroid play an important role and add additional risk.
